Published in Front Mol Neurosci on May 26, 2017
Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev (2001) 13.15
Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci (2006) 12.23
Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem (1999) 3.57
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature (1998) 3.48
Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol (2010) 2.56
Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke (2003) 2.49
Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol (2009) 2.33
Blood pressure and stroke: an overview of published reviews. Stroke (2004) 2.19
Strategies to advance translational research into brain barriers. Lancet Neurol (2008) 2.16
Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res (2000) 2.15
Animal models of head trauma. NeuroRx (2005) 2.09
Pathophysiology of cerebral ischemia and brain trauma: similarities and differences. J Cereb Blood Flow Metab (2004) 2.02
Hypoxic preconditioning protects human brain endothelium from ischemic apoptosis by Akt-dependent survivin activation. Am J Physiol Heart Circ Physiol (2007) 1.92
Role of mitogen- and stress-activated kinases in ischemic injury. J Cereb Blood Flow Metab (2002) 1.91
Mitogen-activated protein kinases: new signaling pathways functioning in cellular responses to environmental stress. J Exp Biol (2003) 1.79
Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci (2003) 1.78
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J (2002) 1.73
Hypoxic induction of endoglin via mitogen-activated protein kinases in mouse brain microvascular endothelial cells. Stroke (2003) 1.70
Clinical trials in traumatic brain injury: past experience and current developments. Neurotherapeutics (2010) 1.69
Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol (1999) 1.62
Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol (2006) 1.55
Inhibition of proteasomal glucocorticoid receptor degradation restores dexamethasone-mediated stabilization of the blood-brain barrier after traumatic brain injury. Crit Care Med (2013) 1.52
Specific role of tight junction proteins claudin-5, occludin, and ZO-1 of the blood-brain barrier in a focal cerebral ischemic insult. J Mol Neurosci (2011) 1.52
Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation (2003) 1.46
Blood-brain barrier pathophysiology in traumatic brain injury. Transl Stroke Res (2011) 1.45
Effects of hypoxia-reoxygenation on rat blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol (2003) 1.45
PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans (2006) 1.44
Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol (2002) 1.44
The role of PPAR activation during the systemic response to brain injury. J Neuroinflammation (2015) 1.44
Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci Lett (2003) 1.33
Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur J Neurol (2007) 1.32
PPARalpha and PPARgamma attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities. FASEB J (2009) 1.29
In vitro central nervous system models of mechanically induced trauma: a review. J Neurotrauma (1998) 1.27
Transport across the endothelium: regulation of endothelial permeability. Handb Exp Pharmacol (2006) 1.26
Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets (2008) 1.24
Overview and introduction: the blood-brain barrier in health and disease. Epilepsia (2012) 1.22
Statins: mechanisms of neuroprotection. Prog Neurobiol (2009) 1.22
H2O2 induces paracellular permeability of porcine brain-derived microvascular endothelial cells by activation of the p44/42 MAP kinase pathway. Eur J Cell Biol (2005) 1.21
PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway. Am J Physiol Heart Circ Physiol (2009) 1.19
Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radic Biol Med (2006) 1.16
Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs (2009) 1.13
WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo. J Immunol (2002) 1.09
Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. American Brain Injury Consortium Study Group. J Neurotrauma (1999) 1.08
Differential susceptibility of cerebral and cerebellar murine brain microvascular endothelial cells to loss of barrier properties in response to inflammatory stimuli. J Neuroimmunol (2006) 1.07
Early modifications in the expression of mitogen-activated protein kinase (MAPK/ERK), stress-activated kinases SAPK/JNK and p38, and their phosphorylated substrates following focal cerebral ischemia. Acta Neuropathol (2003) 1.06
Fenofibrate improves cerebral blood flow after middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab (2009) 1.04
The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans. Brain (2012) 1.04
Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury. Neurosci Lett (2005) 1.04
Delayed activation of PPARgamma by LPS and IFN-gamma attenuates the oxidative burst in macrophages. FASEB J (2001) 1.03
Selection of endogenous control genes for normalization of gene expression analysis after experimental brain trauma in mice. J Neurotrauma (2008) 1.02
Blood-brain barrier breakdown following traumatic brain injury: a possible role in posttraumatic epilepsy. Cardiovasc Psychiatry Neurol (2011) 1.01
Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J Neurotrauma (2007) 1.01
The science of cerebral ischemia and the quest for neuroprotection: navigating past failure to future success. J Neurosurg (2013) 1.00
Peroxisome-proliferator-activated receptor-alpha activation protects brain capillary endothelial cells from oxygen-glucose deprivation-induced hyperpermeability in the blood-brain barrier. Curr Neurovasc Res (2009) 1.00
Effects of the PPAR-α agonist fenofibrate on acute and short-term consequences of brain ischemia. J Cereb Blood Flow Metab (2014) 0.99
Drug delivery to damaged brain. Brain Res Brain Res Rev (2001) 0.98
The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. J Neurotrauma (2005) 0.98
Agonists of peroxisome-proliferator activated receptor-alpha (clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat. Med Sci Monit (2002) 0.96
Peroxisome proliferator-activated receptor-alpha regulates postischemic liver injury. Am J Physiol Gastrointest Liver Physiol (2003) 0.95
Brain edema formation and neurological impairment after subarachnoid hemorrhage in rats. Laboratory investigation. J Neurosurg (2009) 0.95
Influence of age on brain edema formation, secondary brain damage and inflammatory response after brain trauma in mice. PLoS One (2012) 0.94
Glucocorticoid insensitivity at the hypoxic blood-brain barrier can be reversed by inhibition of the proteasome. Stroke (2011) 0.94
PPARα and PPARγ protect against HIV-1-induced MMP-9 overexpression via caveolae-associated ERK and Akt signaling. FASEB J (2011) 0.94
The blood-brain barrier as a target in traumatic brain injury treatment. Arch Med Res (2014) 0.91
Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats. J Pharmacol Exp Ther (2010) 0.91
Molecular mechanism of peroxisome proliferator-activated receptor α activation by WY14643: a new mode of ligand recognition and receptor stabilization. J Mol Biol (2013) 0.91
WY 14643, a potent exogenous PPAR-alpha ligand, reduces intestinal injury associated with splanchnic artery occlusion shock. Shock (2004) 0.90
The pivotal role of astrocytes in an in vitro stroke model of the blood-brain barrier. Front Cell Neurosci (2014) 0.89
Interactions between p38 mitogen-activated protein kinase and caspase-3 in cerebral endothelial cell death after hypoxia-reoxygenation. Stroke (2003) 0.89
Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis: systematic review and meta-regression analysis. Atherosclerosis (2010) 0.89
Compartment- and context-specific changes in tissue-type plasminogen activator (tPA) activity following brain injury and pharmacological stimulation. Lab Invest (2011) 0.89
Ischemia-induced stimulation of cerebral microvascular endothelial cell Na-K-Cl cotransport involves p38 and JNK MAP kinases. Am J Physiol Cell Physiol (2011) 0.89
Addition of NMDA-receptor antagonist MK801 during oxygen/glucose deprivation moderately attenuates the upregulation of glucose uptake after subsequent reoxygenation in brain endothelial cells. Neurosci Lett (2011) 0.89
Treatment of patients with severe head injury by triamcinolone: a prospective, controlled multicenter clinical trial of 396 cases. Res Exp Med (Berl) (1995) 0.88
Transport rankings of non-steroidal antiinflammatory drugs across blood-brain barrier in vitro models. PLoS One (2014) 0.88
Peroxisome proliferator-activated receptor (PPAR) gene profiling uncovers insulin-like growth factor-1 as a PPARalpha target gene in cardioprotection. J Biol Chem (2011) 0.87
Withdrawal of fenofibrate treatment partially abrogates preventive neuroprotection in stroke via loss of vascular protection. Vascul Pharmacol (2009) 0.86
Role of Microvascular Disruption in Brain Damage from Traumatic Brain Injury. Compr Physiol (2015) 0.86
Cost of trauma in Europe. Eur J Neurol (2005) 0.85
PPAR agonist-mediated protection against HIV Tat-induced cerebrovascular toxicity is enhanced in MMP-9-deficient mice. J Cereb Blood Flow Metab (2014) 0.84
Opportunities for neuroprotection in traumatic brain injury. J Head Trauma Rehabil (2000) 0.83
Lung endothelial cells strengthen, but brain endothelial cells weaken barrier properties of a human alveolar epithelium cell culture model. Differentiation (2012) 0.83
PKC-β exacerbates in vitro brain barrier damage in hyperglycemic settings via regulation of RhoA/Rho-kinase/MLC2 pathway. J Cereb Blood Flow Metab (2013) 0.83
Stretch and/or oxygen glucose deprivation (OGD) in an in vitro traumatic brain injury (TBI) model induces calcium alteration and inflammatory cascade. Front Cell Neurosci (2015) 0.82
A novel tool to characterize paracellular transport: the APTS-dextran ladder. Pharm Res (2006) 0.81
Endothelial cells of the brain and other organ systems: some similarities and differences. Prog Neurobiol (1996) 0.80
Validation of in vitro cell culture models of the blood-brain barrier: tightness characterization of two promising cell lines. J Pharm Sci (2008) 0.79
Induction of plasminogen activator inhibitor I by the PPARalpha ligand, Wy-14,643, is dependent on ERK1/2 signaling pathway. Thromb Haemost (2003) 0.79
Imatinib treatment reduces brain injury in a murine model of traumatic brain injury. Front Cell Neurosci (2015) 0.79
Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention. BMC Neurol (2013) 0.78
Pathology of traumatic brain injury. Vet Res Commun (2014) 0.78
Interactions of PPAR-alpha and adenosine receptors in hypoxia-induced angiogenesis. Vascul Pharmacol (2013) 0.78
An Isogenic Blood-Brain Barrier Model Comprising Brain Endothelial Cells, Astrocytes and Neurons Derived from Human Induced Pluripotent Stem Cells. J Neurochem (2016) 0.78
Blood lipids and stroke: what more can we do besides reducing low-density lipoprotein cholesterol? Curr Atheroscler Rep (2011) 0.77
Ischemic factor-induced increases in cerebral microvascular endothelial cell Na/H exchange activity and abundance: evidence for involvement of ERK1/2 MAP kinase. Am J Physiol Cell Physiol (2014) 0.77
Do persons with stroke benefit from statin-fibrate combination therapy? Eur J Intern Med (2015) 0.76
Prospective system analysis of the pre- and early hospital care in severe head injury in Bavaria at a population-based level. Eur Surg Res (2002) 0.75
PPAR-Alpha Agonist Used at the Acute Phase of Experimental Ischemic Stroke Reduces Occurrence of Thrombolysis-Induced Hemorrhage in Rats. PPAR Res (2015) 0.75
Treatment of rats with hypolipidemic compound pirinixic acid protects their hearts against ischemic injury: are mitochondrial K(ATP) channels and reactive oxygen species involved? Physiol Res (2013) 0.75